| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plant pigment (flavonoid) found in red wine, onions, green tea, apples and berries. Quercetin is thought to contribute to anticancer effects through several mechanisms: -Antioxidant Activity: -Induction of Apoptosis:modify Bax:Bcl-2 ratio -Anti-inflammatory Effects: -Cell Cycle Arrest: -Inhibition of Angiogenesis and Metastasis: (VEGF) Cellular Pathways: -PI3K/Akt/mTOR Pathway: central to cell proliferation, survival, and metabolism. -MAPK/ERK Pathway: influencing cell proliferation, differentiation, and apoptosis. -NF-κB Pathway: downregulate NF-κB -JAK/STAT Pathway: interfere with the activation of STAT3 -Apoptotic Pathways: intrinsic (mitochondrial) and extrinsic (death receptor-mediated) pathways Quercetin has been used at doses around 500–1000 mg per day Quercetin’s bioavailability from foods or standard supplements can be low. EMIQ bioavialability is about 3X that of Quercetin (Example Natural Factors brand) Isoquercitrin is high bioaviability and efficiacy but at this time does not seem available as supplement. -Note half-life 11 to 28 hours. BioAv low 1-10%, poor water-solubility, consuming with fat may improve bioavialability. also piperine or VitC. Pathways: - induce ROS production in cancer cells (higher dose). Typicallys Lowers ROS in normal cells(unless it is high dose?)or depends on Redox status?. "quercetin paradox" - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx, - Confusing info about Lowering AntiOxidant defense in Cancer Cells: NRF2↓(some contrary), TrxR↓**, SOD↓(contrary), GSH↓ Catalase↓(contrary), HO1↓(some contrary), GPx↓(some contrary) - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑ - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1, - inhibits glycolysis and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓ - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, - some indication of inhibiting Cancer Stem Cells : CSC↓, CK2↓, Hh↓, CD24↓, β-catenin↓, Notch2↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK, - SREBP (related to cholesterol). - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells
|
| 100- | QC, | Inhibition of Prostate Cancer Cell Colony Formation by the Flavonoid Quercetin Correlates with Modulation of Specific Regulatory Genes |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP |
| 3338- | QC, | Quercetin: Its Antioxidant Mechanism, Antibacterial Properties and Potential Application in Prevention and Control of Toxipathy |
| - | Review, | Var, | NA | - | Review, | Stroke, | NA |
| 1493- | QC, | New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer |
| - | NA, | Bladder, | NA |
| 3337- | QC, | Endoplasmic Reticulum Stress-Relieving Effect of Quercetin in Thapsigargin-Treated Hepatocytes |
| - | in-vitro, | NA, | HepG2 |
| 3336- | QC, | Neuroprotective Effects of Quercetin in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3335- | QC, | Recent advances on the improvement of quercetin bioavailability |
| - | Review, | NA, | NA |
| 3334- | QC, | Pharmacokinetics of Quercetin Absorption from Apples and Onions in Healthy Humans |
| - | Trial, | Nor, | NA |
| 2431- | QC, | The Protective Effect of Quercetin against the Cytotoxicity Induced by Fumonisin B1 in Sertoli Cells |
| - | in-vitro, | Nor, | TM4 |
| 2344- | QC, | Quercetin: A natural solution with the potential to combat liver fibrosis |
| - | Review, | Nor, | NA |
| 2343- | QC, | Pharmacological Activity of Quercetin: An Updated Review |
| - | Review, | Nor, | NA |
| 2342- | QC, | Quercetin Inhibits the Proliferation of Glycolysis-Addicted HCC Cells by Reducing Hexokinase 2 and Akt-mTOR Pathway |
| - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vivo, | NA, | NA |
| 2341- | QC, | Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 2340- | QC, | Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2) |
| - | in-vitro, | OS, | NA |
| 2339- | QC, | Quercetin protects against LPS-induced lung injury in mice via SIRT1-mediated suppression of PKM2 nuclear accumulation |
| - | in-vivo, | Nor, | NA |
| 2338- | QC, | Quercetin: A Flavonoid with Potential for Treating Acute Lung Injury |
| - | Review, | Nor, | NA |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 913- | QC, | Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-435 |
| 1201- | QC, | Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1 |
| - | in-vivo, | BC, | NA |
| 980- | QC, | Dietary Quercetin Exacerbates the Development of Estrogen-Induced Breast Tumors in Female ACI Rats |
| - | in-vivo, | BC, | NA |
| 926- | QC, | PacT, | doxoR, | Tam, | Bioenhancers from mother nature and their applicability in modern medicine |
| - | Review, | Nor, | NA |
| 923- | QC, | Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health |
| - | Review, | Var, | NA |
| 922- | QC, | Quercetin and ovarian cancer: An evaluation based on a systematic review |
| - | Review, | NA, | NA |
| 921- | QC, | Essential requirement of reduced glutathione (GSH) for the anti-oxidant effect of the flavonoid quercetin |
| - | in-vitro, | lymphoma, | U937 |
| 920- | QC, | Interfering with ROS Metabolism in Cancer Cells: The Potential Role of Quercetin |
| - | Review, | NA, | NA |
| 919- | QC, | Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 |
| 918- | QC, | CUR, | VitC, | Anti- and pro-oxidant effects of oxidized quercetin, curcumin or curcumin-related compounds with thiols or ascorbate as measured by the induction period method |
| - | Analysis, | NA, | NA |
| 917- | QC, | BML, | Pap, | Quercetin: A Versatile Flavonoid |
| - | Review, | Nor, | NA |
| 916- | QC, | Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells |
| - | Review, | Ovarian, | NA |
| 915- | QC, | Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management |
| - | Review, | NA, | NA |
| 914- | QC, | Quercetin and Cancer Chemoprevention |
| - | Review, | NA, | NA |
| - | in-vitro, | Pca, | pCSCs |
| 52- | QC, | Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | OS, | U2OS |
| 53- | QC, | Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | NA, | NA, | MDA-MB-468 |
| 54- | QC, | Quercetin‑3‑methyl ether suppresses human breast cancer stem cell formation by inhibiting the Notch1 and PI3K/Akt signaling pathways |
| - | in-vitro, | BC, | MCF7 |
| 55- | QC, | Quercetin inhibits the growth of human gastric cancer stem cells by inducing mitochondrial-dependent apoptosis through the inhibition of PI3K/Akt signaling |
| - | in-vitro, | GC, | GCSCs |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | PATU-8988 |
| 57- | QC, | Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo |
| - | vitro+vivo, | PC, | PC3 |
| 58- | QC, | doxoR, | Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | NA, | CD133+ |
| - | in-vitro, | BC, | MDA-MB-231 |
| 51- | QC, | Effect of Quercetin on Cell Cycle and Cyclin Expression in Ovarian Carcinoma and Osteosarcoma Cell Lines |
| - | in-vitro, | Ovarian, | SKOV3 |
| 61- | QC, | Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | ARPE-19 |
| 62- | QC, | GoldNP, | Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231) |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 63- | QC, | Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells |
| - | in-vitro, | Pca, | NA |
| 64- | QC, | Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | Colon, | SW-620 | - | in-vitro, | Colon, | Caco-2 |
| 65- | QC, | Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB |
| - | in-vitro, | BC, | NA |
| 66- | QC, | Emerging impact of quercetin in the treatment of prostate cancer |
| - | Review, | Pca, | NA |
| 67- | QC, | RES, | Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 98- | QC, | Quercetin postconditioning attenuates myocardial ischemia/reperfusion injury in rats through the PI3K/Akt pathway |
| - | in-vivo, | Stroke, | NA |
| 43- | QC, | Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo |
| - | in-vivo, | Liver, | HepG3 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:140 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid